Health/Science/Wellness, Psychedelics, Technology Solutions and Trends

#163: Rob Davidson, CURE Pharmaceutical

Cannabinoid Connect 163: Rob Davidson, CURE Pharmaceutical

Rob Davidson is the CEO at CURE Pharmaceutical, pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

Topics Discussed:

  • Psychedelics acceptance in the U.S. and current state of research
  • Micro-dosing psychedelics to treat PTSD, Addiction, mental illness, etc.
  • Overview of Oral Thin Film (OTF) Technology
  • CURE’s Schedule 1 DEA License and FDA-registered facility

Listen to the full episode

Watch on YouTube